Patent intelligence · US
US 11166906
Programmable pharmaceutical compositions for chrono drug release
Programmable pharmaceutical compositions for chrono drug release
Patent details — US 11166906
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 9, 2021
- Expiration
- Nov 4, 2041
- Applicant
- Amneal Complex Products Research LLC
- Claims
- 25
- CPC classes
- A61K, A61K31/135, A61K31/137, A61K31/138
Quick answer
US 11166906 (Programmable pharmaceutical compositions for chrono drug release) is held by Amneal Complex Products Research LLC. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Amneal Complex Products Research LLC
- Grant date
- Expiration
- Claims
- 25
- CPC classes
- A61K, A61K31/135, A61K31/137, A61K31/138, A61K31/155, A61K31/165
More from Amneal Complex Products Research LLC
Related pharmaceutical patents in our USPTO index.
-
US 12383522
Baclofen formulations and methods of minimizing patient exposure to metabolite variations
granted -
US 12370163
Levodopa dosing regimen
granted -
US 12303482
Levodopa dosing regimen
granted -
US 12303481
Levodopa dosing regimen
granted -
US 12295931
Levodopa dosing regimen
granted -
US 12263149
Levodopa dosing regimen
granted -
US 12263148
Levodopa dosing regimen
granted -
US 12233166
Extended release compositions comprising pyridostigmine
granted
Frequently asked questions
What is US patent 11166906?
US 11166906 (Programmable pharmaceutical compositions for chrono drug release) is held by Amneal Complex Products Research LLC. Status: granted. Granted Nov 9, 2021. Expires Nov 4, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11166906?
Amneal Complex Products Research LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 32 pharmaceutical patents for this assignee.
When does US 11166906 expire?
Our index shows an expiration date of Nov 4, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.